ASX - By Stock
|
CYP |
Re:
Stem Cell News
|
|
Valueformoney
|
514 |
117K |
2 |
28/04/24 |
28/04/24 |
ASX - By Stock
|
514
|
117K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
Stem Cell News
|
|
Valueformoney
|
514 |
117K |
3 |
26/04/24 |
26/04/24 |
ASX - By Stock
|
514
|
117K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 3Y for Jane Bell
|
|
Valueformoney
|
38 |
18K |
0 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
38
|
18K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 3Y for Jane Bell
|
|
Valueformoney
|
38 |
18K |
34 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
38
|
18K
|
34
|
|
ASX - By Stock
|
CYP |
Re:
Ann: DFU Clinical Trial Enrolment Complete
|
|
Valueformoney
|
22 |
5.5K |
7 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
22
|
5.5K
|
7
|
|
ASX - By Stock
|
OCC |
Re:
Stem Cell Therapy advancements
|
|
Valueformoney
|
456 |
148K |
12 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
456
|
148K
|
12
|
|
ASX - By Stock
|
CYP |
Re:
Ann: EU Approval for Phase 2 CYP-001 Trial in GvHD
|
|
Valueformoney
|
8 |
1.5K |
7 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
8
|
1.5K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
17K |
6.6M |
2 |
04/01/24 |
04/01/24 |
ASX - By Stock
|
17K
|
6.6M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
17K |
6.6M |
2 |
03/01/24 |
03/01/24 |
ASX - By Stock
|
17K
|
6.6M
|
2
|
|
ASX - By Stock
|
PNV |
Re:
30th June 2024 Share Price Prediction
|
|
Valueformoney
|
202 |
67K |
6 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
202
|
67K
|
6
|
|
ASX - By Stock
|
PNV |
Re:
PNV - Chart
|
|
Valueformoney
|
18K |
11M |
1 |
25/06/23 |
25/06/23 |
ASX - By Stock
|
18K
|
11M
|
1
|
|
ASX - By Stock
|
PNV |
Re:
PNV - Chart
|
|
Valueformoney
|
18K |
11M |
0 |
25/06/23 |
25/06/23 |
ASX - By Stock
|
18K
|
11M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection
|
|
Valueformoney
|
275 |
110K |
12 |
19/05/23 |
19/05/23 |
ASX - By Stock
|
275
|
110K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
17K |
6.6M |
9 |
11/05/23 |
11/05/23 |
ASX - By Stock
|
17K
|
6.6M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Valueformoney
|
9.5K |
2.8M |
73 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
9.5K
|
2.8M
|
73
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Valueformoney
|
9.5K |
2.8M |
10 |
06/05/23 |
06/05/23 |
ASX - By Stock
|
9.5K
|
2.8M
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
17K |
6.6M |
15 |
06/04/23 |
06/04/23 |
ASX - By Stock
|
17K
|
6.6M
|
15
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Valueformoney
|
1.6K |
469K |
5 |
27/03/23 |
27/03/23 |
ASX - By Stock
|
1.6K
|
469K
|
5
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Valueformoney
|
1.6K |
469K |
0 |
27/03/23 |
27/03/23 |
ASX - By Stock
|
1.6K
|
469K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
17K |
6.6M |
7 |
04/03/23 |
04/03/23 |
ASX - By Stock
|
17K
|
6.6M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Second Quarter Financial Results Webcast
|
|
Valueformoney
|
56 |
18K |
9 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
56
|
18K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Second Quarter Financial Results Webcast
|
|
Valueformoney
|
56 |
18K |
16 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
56
|
18K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
17K |
6.6M |
2 |
26/01/23 |
26/01/23 |
ASX - By Stock
|
17K
|
6.6M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
17K |
6.6M |
2 |
26/01/23 |
26/01/23 |
ASX - By Stock
|
17K
|
6.6M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
17K |
6.6M |
0 |
26/01/23 |
26/01/23 |
ASX - By Stock
|
17K
|
6.6M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
17K |
6.6M |
0 |
26/01/23 |
26/01/23 |
ASX - By Stock
|
17K
|
6.6M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
17K |
6.6M |
2 |
26/01/23 |
26/01/23 |
ASX - By Stock
|
17K
|
6.6M
|
2
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Investor Presentation
|
|
Valueformoney
|
45 |
16K |
3 |
21/11/22 |
21/11/22 |
ASX - By Stock
|
45
|
16K
|
3
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Investor Presentation
|
|
Valueformoney
|
45 |
16K |
13 |
21/11/22 |
21/11/22 |
ASX - By Stock
|
45
|
16K
|
13
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Remplir Gains Australian Reimbursement
|
|
Valueformoney
|
62 |
18K |
7 |
03/11/22 |
03/11/22 |
ASX - By Stock
|
62
|
18K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Interesting MSC's Article
|
|
Valueformoney
|
20 |
4.3K |
11 |
19/07/22 |
19/07/22 |
ASX - By Stock
|
20
|
4.3K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Valueformoney
|
4.7K |
1.1M |
8 |
16/07/22 |
16/07/22 |
ASX - By Stock
|
4.7K
|
1.1M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
MSB All-time low Party Thread
|
|
Valueformoney
|
396 |
108K |
12 |
04/07/22 |
04/07/22 |
ASX - By Stock
|
396
|
108K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
CHF - MSB's Dark Horse with Multi-billion dollar potential
|
|
Valueformoney
|
516 |
155K |
5 |
30/01/22 |
30/01/22 |
ASX - By Stock
|
516
|
155K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
CHF - MSB's Dark Horse with Multi-billion dollar potential
|
|
Valueformoney
|
516 |
155K |
1 |
30/01/22 |
30/01/22 |
ASX - By Stock
|
516
|
155K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
CHF - MSB's Dark Horse with Multi-billion dollar potential
|
|
Valueformoney
|
516 |
155K |
4 |
30/01/22 |
30/01/22 |
ASX - By Stock
|
516
|
155K
|
4
|
|
ASX - By Stock
|
OCC |
Re:
12 Month Anniversary for Striate+
|
|
Valueformoney
|
62 |
17K |
6 |
16/01/22 |
16/01/22 |
ASX - By Stock
|
62
|
17K
|
6
|
|
ASX - By Stock
|
EX1 |
Re:
Where to from here?
|
|
Valueformoney
|
60 |
19K |
10 |
22/12/21 |
22/12/21 |
ASX - By Stock
|
60
|
19K
|
10
|
|
ASX - By Stock
|
CYP |
Re:
MST Access values CYP at $2.76
|
|
Valueformoney
|
112 |
18K |
8 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
112
|
18K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
MST Access values CYP at $2.76
|
|
Valueformoney
|
112 |
18K |
5 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
112
|
18K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
MST Access values CYP at $2.76
|
|
Valueformoney
|
112 |
18K |
2 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
112
|
18K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
MST Access values CYP at $2.76
|
|
Valueformoney
|
112 |
18K |
5 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
112
|
18K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Q1 Financial Results and Operational Highlights
|
|
Valueformoney
|
124 |
38K |
2 |
24/11/21 |
24/11/21 |
ASX - By Stock
|
124
|
38K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
MST Access values CYP at $2.76
|
|
Valueformoney
|
112 |
18K |
7 |
24/11/21 |
24/11/21 |
ASX - By Stock
|
112
|
18K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
MST Access values CYP at $2.76
|
|
Valueformoney
|
112 |
18K |
1 |
24/11/21 |
24/11/21 |
ASX - By Stock
|
112
|
18K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB and Oaktree Conclude Refinancing of Senior Debt Facility
|
|
Valueformoney
|
451 |
113K |
5 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
451
|
113K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB and Oaktree Conclude Refinancing of Senior Debt Facility
|
|
Valueformoney
|
451 |
113K |
7 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
451
|
113K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Valueformoney
|
4.7K |
1.1M |
3 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
4.7K
|
1.1M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
15 Days until doubt is removed
|
|
Valueformoney
|
953 |
289K |
1 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
953
|
289K
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Valueformoney
|
10K |
3.0M |
2 |
07/10/21 |
07/10/21 |
ASX - By Stock
|
10K
|
3.0M
|
2
|
|